Cancer Center Clínica Universidad de Navarra / CIMA
The University of Navarra's cancer centre in Pamplona and Madrid, known for myeloma, immunotherapy research and one of Spain's first proton therapy units.
The Cancer Center Clínica Universidad de Navarra combines the university hospital's Pamplona and Madrid campuses with the CIMA research centre. Jesús San Miguel and Bruno Paiva have led international myeloma trials and developed next-generation flow cytometry for minimal residual disease, Ignacio Melero's laboratory is a reference in cancer immunotherapy and intratumoural immunostimulation, and Felipe Prósper's group works on cell therapy and gene therapy. The Madrid campus opened a proton therapy unit in 2020, among the first in Spain. The centre is OECI-accredited and offers early-phase trials, CAR-T and comprehensive genomic profiling to private and insured patients.
- Multiple myeloma and MRD
- Cancer immunotherapy (Melero)
- Proton therapy (Madrid)
- Cell and gene therapy
- CIMA research
Pages like this
not linked directly; found by shared links- InstitutionSylvester Comprehensive Cancer Center, University of Miami
Shares Proton therapy, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Multiple myeloma.
- InstitutionShandong Cancer Hospital and Institute
Shares Abscopal effect, Proton therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- InstitutionNational Cancer Centre Singapore
Shares TIL therapy, Proton therapy, Hepatocellular carcinoma, CAR-T cell therapy.
- InstitutionHospital Universitario 12 de Octubre
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Multiple myeloma, CAR-T cell therapy.
- InstitutionIUCT Oncopole – Institut Universitaire du Cancer de Toulouse
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Multiple myeloma, CAR-T cell therapy.
- InstitutionTaipei Veterans General Hospital
Shares Hepatocellular carcinoma, CAR-T cell therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- IdeactDNA-guided adjuvant therapy in stage II-III melanoma
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Melanoma, Immune checkpoint inhibitors.
- PairingPD-1 failure → TIL therapy
Shares TIL therapy, Melanoma, Immune checkpoint inhibitors.